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HLA-C locus mismatches (MMs) are the most frequent class I disparities in unrelated 
hematopoietic stem cell transplantation (HSCT) and have a detrimental impact on clinical 
outcome. Recently, a few retrospective clinical studies have reported some variability in 
the immunogenicity of HLA-C incompatibilities. To get better insight into presumably per-
missive HLA-C MMs, we have developed a one-way in vitro mixed lymphocyte reaction 
(MLR) assay allowing to quantify activated CD56−CD137+CD8+ lymphocytes in HLA-C 
incompatible combinations. T cell-mediated alloresponses were correlated with genetic 
markers such as HLA-C mRNA expression and the number of amino acid (aa) MMs in 
the α1/α2 domains (peptide-binding region). Because of the high rate of HLA-DPB1 
incompatibilities in HLA-A-, B-, C-, DRB1-, and DQB1-matched unrelated HSCT patient/
donor pairs, the impact of HLA-DPB1 mismatching, a potential bystander of CD4+ T cell 
activation, was also considered. Heterogeneous alloresponses were measured in 63 
HLA-C-mismatched pairs with a positive assay in 52% of the combinations (2.3–18.6% 
activated CTLs), representing 24 different HLA-A~B~DRB1~DQB1 haplotypes. There 
was no correlation between measured alloresponses and mRNA expression of the 
mismatched HLA-C alleles. The HLA-C*03:03/03:04 MM did not induce any positive 
alloresponse in five MLRs. We also identified HLA-C*02:02 and HLA-C*06:02 as mis-
matched alleles with lower immunogenicity, and HLA-C*14:02 as a more immunogenic 
MM. A difference of at least 10 aa residues known to impact peptide/T cell receptor 
(TCR) binding and a bystander HLA-DPB1 incompatibility had a significant impact on 
CTL alloreactivity (p = 0.021). The same HLA-C MM, when recognized by two different 
responders with the same HLA haplotypes, was recognized differently, emphasizing the 
Abbreviations: HSCT, hematopoietic stem cell transplantation; aa, amino acid; MLR, mixed lymphocyte reaction; TCR, T cell 
receptor; PBR, peptide-binding region; MM, mismatch.
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inTrODUcTiOn
HLA class I molecules are expressed on almost all nucleated 
cells and play a key role in the immune responses to pathogens, 
cancer cells, and autoantigens. In addition to their extremely 
high level of allelic polymorphism, they are also characterized 
by variable levels of expression potentially influencing their 
function. Although HLA-C antigens are expressed at a lower 
level compared to HLA-A and B antigens (1–4), they are also 
well recognized by alloreactive T cells and thus are bona fide 
transplantation antigens. Several studies have recently reported 
variability in the expression of different HLA-C serotypes, as 
determined at the cell surface or mRNA steady-state levels 
(5–8). Variability within HLA-A serotypes has also been recently 
reported (9). A search for genetic markers of HLA-C expression 
led to the description of two relevant polymorphisms. First, a 
SNP located 35  kb (rs9264942) upstream of the HLA-C locus 
has been reported to correlate with the level of HLA-C expres-
sion and with the control of HIV viremia (7). HLA-C allotypes 
with a higher expression marked by the −35C genotype have 
been shown to correlate with a better control of HIV infection 
and to a more efficient recognition by CTLs (5, 7). The second 
polymorphism in the 3′-UTR of HLA-C gene is the 263del/
ins variant affecting the miRNA-148a binding and controlling 
at least partly HLA-C mRNA stability (8). Control of HLA-C 
expression is most likely more complex because of the lack 
of consensus between genetic markers and expression levels 
reported by different studies. For example, the C*14:02 allotype, 
reportedly classified as high if not the highest (5) expression 
allele, is characterized by the 263ins variant associated with low 
expression (8). The correlation of these genetic markers with 
expression levels has been challenged by a few other studies (6, 
10, 11). The studies analyzing HLA-C cell surface expression 
or mRNA steady state were hampered by the fact that it was 
not possible to discriminate between the two HLA-C alleles in 
heterozygous donors. By using group-specific polymerase chain 
reaction (PCR), individuals expressing the same HLA-C allele 
did show variability in mRNA steady-state amounts within a 
given serotype that could possibly be correlated with specific 
haplotypes (6).
As determined in retrospective clinical studies in mismatched 
unrelated hematopoietic stem cell transplantation (HSCT), 
immunogenicity of HLA-C mismatches (MMs) has been 
reported to be affected by specific amino acid (aa) residues in the 
peptide-binding region (PBR). In particular, HLA-C MM involv-
ing residue 116 has been reported to be associated with higher 
risk of aGVHD and mortality (12–14).
Two studies, so far, have tested the impact of HLA-C expression 
level on the clinical outcome of 9/10-matched unrelated HSCT. 
As a proxy of HLA-C expression, both studies used the previously 
reported mean fluorescence intensity (MFI) values of anti-HLA-
C DT9 antibody binding determined in 200 African-American 
and in 50 European-American – mostly heterozygous – donors 
(5). Using 1,975 9/10-matched HSCT of the International 
Histocompatibility Working Group in HCT, Petersdorf et  al. 
(15) compared patients with low expression mismatched C*03 
and C*07 allotypes and high expression C*01 and C*14 allotypes 
and found that high expression mismatched HLA-C alleles were 
associated with increased mortality. On the other hand, analyzing 
1,965 pairs with single HLA-C MMs, Morishima et al. (16) did 
not find any correlation between increasing level of expression 
of patient’s mismatched HLA-C allele and aGVHD or TRM risk, 
although patients’ HLA-C*14:02 was significantly associated with 
poor outcome. The same MFI values have also been applied to 
analyze a possible correlation with in vitro CTLp frequency to sin-
gle HLA-C MMs. CTLp outcome was reported to correlate both 
with the expression of the donor and of the recipient mismatched 
HLA-C antigens (17).
Besides HLA-C MMs, HLA-DPB1 MMs are the most frequent 
disparities in unrelated HSCT with detrimental effects on acute 
GVHD and other transplantation-related risks (18–20). Specific 
HLA-DPB1 MMs with higher potential for T cell allorecognition, 
as well as expression levels of HLA-DPB1 variants, have been 
reported to be associated with acute GVHD in unrelated HSCT 
(21, 22).
In this study, we investigated the CTL alloresponse induced 
by single HLA-C MMs by quantifying CD8+CD56−-activated T 
lymphocytes in an in  vitro mixed lymphocyte reaction (MLR) 
assay. Our aim was to correlate the immunogenicity of HLA-C 
MM with HLA-C mRNA expression levels, with disparities in aas 
known to be relevant for peptide binding and/or T cell recep-
tor (TCR) recognition, and also with concomitant HLA-DPB1 
incompatibilities.
MaTerials anD MeThODs
Patients and Donors
Peripheral blood mononuclear cells (PBMCs) were purified using 
standard Ficoll procedure from blood collected from patients 
and donors who have been analyzed by the National Reference 
Laboratory for Histocompatibility (LNRH) for unrelated HSC 
donor searches. HLA high resolution typing was performed 
by reverse PCR-sequence-specific oligonucleotides typing on 
role of the T-cell repertoire of responding cells. In conclusion, mismatched HLA-C alleles 
differing by 10 or more aas in the peptide/TCR-binding region, when occurring together 
with HLA-DPB1 incompatibilities, should be considered as high-risk MMs in unrelated 
HSCT.
Keywords: hla-c, alloreactivity, cytotoxic T lymphocytes, hematopoietic stem cell transplantation, mixed 
lymphocyte reaction
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microbeads arrays (One Lambda, Canoga Park, CA, USA), by 
PCR-sequence-specific primers (Genovision, Milan Analytika 
AG, Switzerland), and by monoallelic sequencing (Protrans, 
Hockenheim, Germany). This study has been approved by the 
ethical committee of the Geneva University Hospitals (reference 
#08-208R). For many years, in  vitro cellular assays (CTLp and 
MLR) have been performed at LNRH as part of the routine histo-
compatibility testing for unrelated HSC donor searches.
Mixed lymphocytes reactions
For allogenic stimulation, one-way MLRs were performed using 
thawed cryopreserved PBMC, which were cryopreserved in 
RPMI 1640 medium (Gibco Life Technologies, Oslo, Norway) 
supplemented with l-glutamine, penicillin and streptomycin 
(Gibco), 10% dimethylsulfoxid (Merck, Darmstadt, Germany), 
and 20% fetal calf serum (Gibco). Responder cells (2 × 106) were 
stimulated at a ratio of 1:1 with 30 Gy irradiated stimulator cells 
in RPMI 1640 medium (Gibco) supplemented with l-glutamine, 
penicillin and streptomycin (Gibco), and 10% human AB serum 
(own preparation). Twenty units per milliliter rIL-2 (Peprotech, 
London, UK) were added at days 3, 7, and 11. After 13 days of 
culture, responding T cells were restimulated overnight with 
irradiated PKH-2 (Sigma-Aldrich, Buchs, Switzerland)-labeled 
PHA blasts obtained by activation of non-irradiated stimula-
tory PBMCs with 1  μg/ml PHA (Gibco). The percentage of 
CD137+PKH-2−CD8+CD56− viable T cells was quantified by 
flow cytometry using APC-labeled anti-human CD8a, PerCP/
Cy5.5 anti-human CD56 (BioLegend, Fell, Germany), and FITC-
labeled anti-human CD137 (Milteny Biotec, Bergisch-Gladbach, 
Germany) antibodies, as well as APC- and FITC-labeled murine 
IgG1 isotype controls (BD Bioscience, Allschwil, Switzerland). 
As controls, half of the cultures were also restimulated with 
autologous PHA blasts. The percentage of activated CD8+ 
T  cells referred as Δ%CD137+CD8+ equals the percentage of 
CD137+CD8+CD56− cells measured in cultures restimulated with 
stimulator cells minus the percentage of CD137+CD8+CD56− 
cells measured in cultures restimulated with autologous cells (23). 
Data acquisition was performed on 5,000 gated CD8+CD56− cells 
using the ACCURI-C6 cytometer (BD) and the CFLOWPLUS 
analysis software.
An MLR assay with Δ%CD137+CD8+ ≥2% was considered 
as positive, this threshold corresponding to the variability 
observed in unstimulated cultures. As positive controls to 
monitor responsiveness of the responder cells and ability of 
stimulator cells to induce an alloresponse, responder cells were 
stimulated in parallel cultures with allogeneic stimulatory cells 
mismatched for several HLA-A, B, and C alleles, and similarly, 
stimulator cells were used to stimulate allogeneic HLA-A-, B-, 
and C-mismatched responder cells. In this study, only MLRs with 
a positive allogenous control were considered. Of the 63 MLRs, 
12 could be repeated at different dates, as a way to control for 
reproducibility of our experiments, because enough cells had 
been cryopreserved. With two exceptions, all repeated cultures 
(eight duplicates and two triplicates) allowed the same positive 
versus negative alloresponse discrimination (SD of measured 
alloreactivity varying between 0.11 and 4.66, including seven 
replicates with SD below 1.8).
hla-c mrna Quantification
Total RNA was extracted from thawed stimulator cells prior to 
irradiation using the RNeasy Micro kit (Qiagen, Valencia, CA, 
USA) and according to the manufacturer’s instructions. RNA 
was reverse transcribed with the M-MLV H-Minus (Promega, 
Madison, WI, USA) reverse transcriptase and random oligo dT 
15mer-primers in the presence of rRNAsin (Promega). HLA-C 
cDNA was quantified relative to 18S RNA, as previously described 
(6), using SYBR Green/Rox (Abgene, Epsom, UK)-based quan-
titative real-time PCR on a real-time PCR System 7300 using the 
SDS software version 1.3.10.2 (Applied Biosystems). The results 
were expressed as 100/ΔCt (where ΔCt is Ct HLA-C − Ct 18S).
Differences in PBr residues 
and statistical analyses
HLA-C mature protein sequences were retrieved from the IMGT/
HLA database (http://www.ebi.ac.uk/ipd/imgt/hla/) and used to 
compute the difference in aa for each allele pair (i.e., the number 
of mismatched residues in the PBR between the stimulator and 
the responder). Each residue was categorized as forming, or not, 
the pocket-like structures of the PBR, as being involved, or not, 
in peptide binding according to various biological, chemical, or 
physical properties [see Ref. (24) and references therein] and as 
being a putative recognition site for the TCR (25).
Logistic and linear modeling analyses were performed using 
the R statistical computing environment to assess individually 
or jointly the association(s) between the number of mismatched 
residues, HLA-DPB1 matching, expression of the stimulator 
allele and variation at positions 80 and 116 (i.e., the predictor 
or independent variables), and alloreactivity [i.e., the response 
or dependent variable considered, respectively, as (a) positive or 
negative or (b) measured along a continuous axis]. The second 
approach allowed avoiding too strong assumptions based on an 
arbitrary cutoff value of alloreactivity. The linear models were 
validated, whenever appropriate, using diagnostic plots.
resUlTs
heterogeneity of the cTl alloresponse 
to hla-c alleles
The CTL alloresponse was measured in 63 in vitro MLR assays 
including 18 different target HLA-C alleles. With two exceptions, 
all HLA-C MMs differed in the α1/α2 domains. The 18 tar-
get alleles included all frequent C allotypes present in populations 
of European origin except C*08:02. Seven MLR combinations 
consisted in HLA-C allele MMs within the C*02 (two pairs) and 
C*03 serotype (five pairs). The C*02 combinations consisted of 
the C*02:02/02:29 incompatibility that differs at residue 265 in 
the α3 domain. The C*03 combinations were C*03:03/03:04 MMs 
differing by a single residue at position 91 in the α1 domain. The 
remaining 56 pairs consisted in HLA-C antigen MMs (26).
For each of the 18 different HLA-C target  alloantigens, 
1–9 MLRs were performed with a total of 24 different HLA-
A~B~DRB1~DQB1 shared haplotypes. The overall results 
(Figure  1) showed a heterogeneous response toward single 
HLA-C MM: 52% of all combinations led to a positive assay 
FigUre 2 | Box and whisker plots of hla-c mrna expression 
quantified by rT-Pcr in stimulator cells at day 0 inducing a negative 
versus a positive (cutoff = 2% ΔcD137+cD8+ cells) alloresponse.
FigUre 1 | heterogenous alloresponse tested by in vitro mixed 
lymphocyte reaction (Mlr)/flow cytometry assays in 63 
responder/stimulator cell combinations that were characterized by 
a single hla-c mismatch. The mismatched HLA-C allele of the 
stimulator cells and the %ΔCD137+CD8+ cells induced after restimulation 
at day 14 are indicated (see Materials and Methods). The cutoff of 2% 
ΔCD137+CD8+ cells is indicated by the dashed line. Activation of CD8+ 
NK cells (ranging between 0.2 and 1.2% CD8+CD56+CD137+ cells, 
results not shown) was not taken into consideration. Overall, 24 different 
shared HLA-A~B~DRB1~DQB1 haplotypes were tested (data not 
shown). Twelve MLRs were repeated but dotted as single mean 
%ΔCD137+CD8+ values. Black dots represent MLRs with HLA-C MMs 
located in α1/α2 domains and HLA-DPB1 MMs. Blue triangles represent 
MLRs with HLA-C MMs located in α1/α2 domains and matched 
HLA-DPB1. Open circles represent MLRs with C*03:03/03:04 MMs and 
C*03:04/03:03 MMs, all HLA-DPB1 MMs. Open triangles represent 
MLRs with HLA-C MMs located outside α1/α2 domains (C*02:29/02:02, 
C*02:02/02:29) and matched HLA-DPB1.
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within a range of 2.3–18.6% CD137+CD8+ T cells, whereas 48% 
were negative (<2%).
The CTL alloresponses toward the same HLA-C MM show 
that the C*14:02 target alloantigen is recognized at a higher level, 
with five of seven pairs leading to a positive response varying 
between 2.7 and 18.6%. Similarly, the C*03:03 target alloantigen 
was well recognized by non-C*03:04 responders (3/5 positive 
tests, 4.7–15.9%). Furthermore, 6/6 C*06:02 and 5/6 C*02:02 
MMs were not able to induce a CD8+ T cell response. Only 
one C*02:02 target  alloantigen was weakly recognized by 3.4% 
CD137+CD8+ T cells. All of the five C*03:03/03:04 MM pairs 
were “silent” MMs, either with the C*03:03 (two pairs) or the 
C*03:04 (three pairs) alleles as target alloantigens (open circles 
in Figure 1).
impact of hla-c expression
In order to detect a possible correlation between CTL allore-
sponses and levels of HLA-C expression, we quantified mRNA 
steady-state levels of the stimulator PBMCs at day 0 of the 
MLR. As presented in Figure 2, no correlation between the CTL 
alloresponse and quantified HLA-C mRNA steady-state levels 
could be disclosed when data were analyzed altogether (non-
significant coefficients in single and multiple linear regressions, 
results not shown). Exclusion of the 02:29/02:02, 02:02/02:29, 
03:04/03:03, and 03:03/03:04 pairs (single MM in α3 domain or 
in α2 domain but not seen by the TCR) did not significantly alter 
the results. We also classified the 63 assays performed in our 
study by using previously published quantitative measurement 
of MFIs (5, 15) to impute expression levels of HLA-C allotypes. 
The results do not show any significant correlation between the 
imputed expression level of the target HLA-C antigen and the 
CTL alloresponse (p =  0.637, Figure  3).
impact of Mismatched aa residues 
affecting Peptide/Tcr Binding
In order to analyze the impact of functionally relevant aa MMs, 
we compared the alloresponse with the number of aa differences 
in the α1/α2 domains. The two pairs with a C*02:02/02:29 
MM were excluded because the two alleles have identical 
sequences in the α1/α2 domains. As determined in 61 pairs, 
between 1 and 15 aa differences were recorded (mean = 10.6, 
median =  12, not shown). On average, the number of mis-
matched residues was higher in the MLR pairs that resulted in 
a positive CTL alloresponse (Figure 4 and logistic regression, 
coefficient  =  0.158, p  =  0.037). The mismatched residues 
affected predominantly those involved in peptide binding 
relative to the TCR contact residues. Taking into account both 
the number of aa differences (coefficient =  0.169, p =  0.026) 
and the HLA-DPB1 matching (coefficient = 1.27, p = 0.06) as 
predictor variables, only the aa differences appeared to have an 
impact (additive model, interaction not significant). However, 
when the C*03:03/03:04 MM pairs were omitted, the aa differ-
ences were not significant anymore, while HLA-DPB1 became 
borderline significant (coefficient = 1.44, p = 0.048). Measuring 
alloreactivity along a continuous axis and testing several 
predictor variables (Figure 5), only HLA-DPB1 matching was 
significant either considering the 61 pairs (linear regression, 
FigUre 3 | scatter plot of hla-c expression [mean fluorescence intensity (MFi) values according to ref. (5, 15)] and alloreactivity (%ΔcD137+cD8+ 
cells). A label is plotted for each stimulator allele at the top of the graph, indicating its corresponding MFI value. The linear regression through the data points is 
shown in red, and the confidence interval is in yellow (coefficient = 0.004, p = 0.637).
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coefficient =  2.82, p =  0.031) or omitting C*03:03/03:04 MM 
pairs (coefficient =  2.74, p =  0.039).
The ratio of pairs with aa116 MMs was similar in negative 
(20/31) and positive MLRs (19/30). Among aa116 MM pairs, 
those with HLA-C expression above the mean value (11.23) had 
a higher rate of positive MLR (53% compared to 31% in pairs with 
low expression, not significant). MMs at positions 77 and 80 were 
not associated with T cell alloreactivity (data not shown).
Of 44 pairs with ≥10 HLA-C aa MMs, 24 induced a positive 
alloresponse and 20 were negative. A strong correlation was 
disclosed with the HLA-DPB1-matching status since 87.5% of 
the positive pairs and 55% of the negative pairs were HLA-DPB1 
incompatible (Figure 4). Altogether, positive CTL alloresponses 
occurred more frequently in HLA-C-mismatched combinations 
that differed by ≥10 residues and were HLA-DPB1 incompatible 
(p = 0.021, Fisher’s test). It is relevant to note that, as shown in 
Figure 1, none of the HLA-DPB1-matched pairs (blue triangles) 
induced a high alloreactivity, with all HLA-DPB1-matched pairs 
showing <3.75% CD137+CD8+ T cells.
role of responder cells
We next asked whether CTL allorecognition of the same alloan-
tigen was similar when two different responder cells exhibiting 
the same two HLA-A~B~C~DRB1~DQB1 haplotypes were 
tested. As shown in Figure 6A, the C*03:03 MM was recognized 
by only one of the three C*07:01-positive responders (12.9, 
0.56, and 1.2%). In Figure  6B, the C*14:02 MM was much 
more efficiently recognized by one of the two C*02:02-positive 
responders (12.6 and 3.1%). On the other hand, allorecognition 
was more similar in the response to the C*16:02 allele (5.2 and 
4.5%) (Figure  6C) and to the C*17:01 allele (1.4 and 2.8%) 
(Figure  6D). Therefore, the results confirm that the level of 
HLA-C expression cannot alone account for the strength of the 
alloresponse because the same incompatibility was recognized 
quite differently by two (Figure  6B) or three (Figure  6A) 
responder cells sharing the same HLA-A~B~C~DRB1~DQB1 
haplotypes. All pairs tested within the four experiments were 
HLA-DPB1 incompatible, except the negative pair in the experi-
ment depicted in Figure  6D. This is in accordance with the 
FigUre 4 | Box and whisker plots of the number of mismatched residues at hla-c between the stimulator and the responder alleles and 
alloreactivity defined as negative or positive (cutoff = 2% ΔcD137+cD8+ cells). The boxes correspond to the interquartile range, the median is the thick line 
inside the box, and whiskers extend up to observations that are outside the box for less than 1.5 times the interquartile range. No outliers to these limits were 
observed. The observations are also plotted individually with information on two predictor variables: matching at HLA-DPB1 is indicated by two different colors (blue 
for matched and red for mismatched HLA-DPB1), while variation at position 116 is indicated by the shape of the dots (a reversed triangle for matched and a circle 
for mismatched).
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notion that the TCR repertoire of the responder is a crucial 
factor that governs allorecognition (27).
role of stimulator cells
In order to avoid the impact of the responders’ TCR repertoire, 
we compared MLRs of 9/10-matched pairs using a single 
responder (i.e., 1 single TCR repertoire) and 2–3 stimula-
tor cells from different donors who have exactly the same 2 
HLA-A~B~C~DRB1~DQB1 haplotypes with the same HLA-C 
MM. As shown in four different mismatched combinations 
(Figure 7), the same MM did not induce the same alloresponse. 
Only one of the two HLA-C*04:01-positive stimulators was 
able to induce a high alloresponse of the C*06:02-mismatched 
responder (3.1 and 9.6%, Figure  7A). C*07:01 expressed in 
three different stimulator cells was efficiently recognized by 
the C*03:03 responder in two of the three pairs (6.8, −1.2, 
and 2.7%, Figure  7B). The C*01:02 responder did recognize 
the C*15:02 MM in only one of the two stimulator cells 
(1.1 and 5.7%, Figure  7C). The C*15:02 allele was not or 
poorly recognized by the C*14:02 responder (−2.9 and 2.3%, 
Figure  7D). When the levels of HLA-C mRNA were plotted 
against the %CD137+CD8+ T cells induced in the alloreponse, 
the results disclosed a positive but non-significant correlation 
(r  =  0.42, p  =  0.056) (Figure  7E). Furthermore, in two of 
the four experiments (Figures 7A,C), the stimulator cells that 
induced the highest alloresponse were HLA-DPB1 mismatched, 
whereas in the two other experiments, all stimulators were 
HLA-DPB1 incompatible. Interestingly, among the five positive 
MLRs with HLA-DPB1 MMs, four of five had a “high expres-
sion” phenotype according to Ref. (22).
FigUre 5 | scatter plot of the number of mismatched residues at hla-c between the stimulator and the responder allele and alloreactivity 
(%ΔcD137+cD8+ cells). Information on several predictor variables is plotted: matching at HLA-DPB1 is indicated by two different colors (blue for matched and 
orange for mismatched HLA-DPB1), mRNA expression of the stimulator HLA-C allele is indicated by the size of the dots, while variation at position 116 is indicated 
by the shape of the dots (a reversed triangle for matched and a circle for mismatched). The cutoff value considered for positive/negative alloreactivity is shown by 
the red dotted line.
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DiscUssiOn
The success of unrelated HSCT is strongly influenced by HLA 
matching. For patients with less common HLA haplotypes, 
9/10-matched donors with a single HLA-C MM can represent 
the best option, but such incompatible transplants are charac-
terized by increased risk of posttransplant complications (15, 
16, 28). Some clinical studies have proposed that the allore-
sponse may vary with the nature of the HLA-C MM (12–14), 
although reliable prediction of less detrimental MMs remains 
a difficult task. In order to address this question, we measured 
CTL alloreactivity against incompatible HLA-C alleles in a one-
way MLR in  vitro assay. By quantifiying CD137+CD8+CD56− 
T   lymphocytes at day 14, we focused on T cell but not NK 
cell-mediated alloreactivity. The MLR assay had been developed 
previously to disclose a silent allele MM in the HLA-B44 
serotype (23). In parallel, we determined the impact of the 
expression levels of the mismatched HLA-C alleles as measured 
by real-time RT-PCR. We also investigated the possible role of 
mismatched residues in the PBR (α1/α2 domains) that affect 
peptide and/or TCR binding and the HLA-DPB1-matching 
status for each pair tested in the MLRs. The outcome of 63 
MLR assays showed a large heterogeneity of the alloresponse 
with 52% positive tests. We first confirmed that MMs differing 
either outside the α1/α2 domains (C*02:02/02:29, α3 domain) 
or within the α1/α2 domains but not affecting peptide/TCR 
binding (C*03:03/03:04, residue 91 in the α2 domain) are not 
recognized by CD8+ alloreactive T cells and could therefore be 
considered as permissive MMs (28, 29). Next, we confirmed that 
the C*14:02 MM was able to induce a positive alloresponse in 
five of seven tested combinations, with two responses among 
the highest values (>10%) of CD137+CD8+ T lymphocytes. 
In addition, the MLRs revealed that C*02:02 or 06:02 MMs were 
not recognized in 11/12 individuals. Interestingly, a report on 
FigUre 7 | Mixed lymphocyte reactions (Mlrs) between different hla-c MM stimulators and the same responder. Each panel represents MLRs 
between responder cells isolated from the same individual and HLA-C MM stimulator cells from two to three different individuals. MLRs of each panel were 
performed in parallel (i.e., at the same time) for each experiment and represent four different HLA-C MM: the mismatched HLA-C alleles of the responder and the 
stimulator are indicated below each panel. Alloresponses are given as %ΔCD137+CD8+ cells (2% cutoff indicated by the dashed line). All pairs were DPB1 
incompatible except two pairs [dashed bars in (a,c)]. (e) shows the correlation between HLA-C mRNA expression of the stimulator cells and the induced 
alloresponse (%ΔCD137+CD8+ cells): r = 0.42, p = 0.056. Triangles correspond to HLA-DPB1-matched pairs. All other MLRs were HLA-DPB1 mismatched. Colors 
in (e) correspond to those used in (a–D).
FigUre 6 | Mixed lymphocyte reactions (Mlrs) between different 
responders and the same hla-c MM stimulator. Each panel represents 
MLRs between cells of three (a) or two (B–D) responders and one stimulator. 
MLRs of each panel were done in parallel (i.e., at the same time) for each of 
the four experiments (a–D) and represent four different HLA-C MMs: the 
mismatched HLA-C alleles of the responder and the stimulator are indicated 
below each panel. Alloresponses are given as %ΔCD137+CD8+ cells (2% 
cutoff indicated by the dashed line). All pairs tested in (a–c) were HLA-DPB1 
mismatched. In experiment (D), the two pairs (one positive, one negative) 
were HLA-DPB1 matched.
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CTLp assays performed with HLA-C 9/10-mismatched patient/
donor pairs had previously reported that 4/5 C*02:02-positive 
patients were not recognized by the CTLp assay (30). The 
overall comparison of the 63 MLRs did not reveal an impact of 
the HLA-C mRNA expression levels (Figure 2). In particular, 
a wide distribution of expression levels was observed among 
the negative MLR combinations. For comparison purposes with 
previous clinical studies (15, 16), we also analyzed the allore-
sponses measured in the 63 MLRs on the basis of MFIs taken as 
proxies of HLA-C expression levels (5, 15). In accordance with 
the results of the Japan Marrow Donor Program study (16), we 
did not find any correlation with HLA-C expression using these 
proxies (Figure 3), although, again, C*14:02 MMs were indeed 
recognized more efficiently.
Because T cell-mediated alloreactivity is strongly influenced 
by the peptide repertoire of the stimulating cells (27, 31, 
32), we compared the CTL responses with the number of aa 
residues differences known to impact peptide/TCR binding. 
As shown in Figure  4, a higher mean number of aa differ-
ences was disclosed in the positive MLRs, in accordance with 
data showing that T cell alloreactivity results from peptide-
dependent structural mimicry (27, 32, 33). However, this result 
was strongly influenced by the C*03:03/03:04 MM pairs and 
was not confirmed when alloreactivity was considered along a 
continuous distribution.
An additional genetic factor influencing the alloresponse 
toward incompatible HLA-C antigens was HLA-DPB1 match-
ing. Indeed, HLA-DPB1 MMs are expected to induce a CD4+ 
T helper response (34) that might increase CTL stimulation as 
a bystander effect. Clinical studies have demonstrated an impact 
of DPB1 disparities on the outcome of HSCT (18–20). A higher 
rate of HLA-DPB1 matching was observed among the negative 
MLRs (32 versus 14% in the positive pairs). When taking into 
account both parameters, i.e., ≥10 aa differences in the PBR and 
HLA-DPB1 MM, a positive correlation with CTL response was 
disclosed (p = 0.021). On the other hand, HLA-DPB1-matching 
status is not the only important parameter because five MLRs 
showing wide differences in the ratio of CD137+CD8+ T cells 
(Figures 6A,B) were all HLA-DPB1 incompatible.
9Bettens et al. Allorecognition of HLA-C Mismatches
Frontiers in Immunology | www.frontiersin.org December 2016 | Volume 7 | Article 584
To avoid variability of alloresponses due to peptide/MHC 
complexes (polymorphism and expression), we used the same 
HLA-C MM cells to stimulate different responder cells that were 
HLA matched among each other. Since in three of four experi-
ments, a given HLA-C MM was able to induce different allore-
sponses when tested against two or three different responders 
with exactly the same HLA haplotypes (Figure 6), this indicates 
that CTL activation is modulated by the TCR repertoire of the 
responder cells. HLA-C-restricted T lymphocytes are important 
actors of antiviral immunity [reviewed by Blais et  al. (35)]. 
Because HLA-C is less saturated with endogenous peptides (36), 
access to viral peptides might increase the repertoire diversity 
of peptides bound to mismatched HLA-C antigens and thereby 
increase the relative frequencies of cross-reactive CTLs. TCR 
repertoire analysis of the responding cells should help in better 
understanding the variability of the T cell alloresponse.
Nevertheless, when both the effects of the number of aa 
MMs and of TCR repertoire were neutralized by stimulating 
the same responder cells expressing the same HLA-C MM on 
identical HLA haplotypes, variable alloresponses were observed 
(Figures 7A–D). In this case, CTL activation did show some weak 
correlation with HLA-C mRNA expression of the stimulator allele 
(Figure 7E), although this result should be interpreted cautiously 
because in two of the four experiments the low (Figure 7A) or 
negative (Figure  7C) alloresponse corresponded to the HLA-
DPB1-matched pairs.
We acknowledge some limitations of our study. The in vitro 
MLR assay can only be a simplified model of the alloreaction 
occurring in HSCT. Yet, it allowed to confirm the permissiveness 
of the C*03:03/03:04 MM as well as the higher risk of aGVHD and 
transplant-related mortality conferred by patient’s C*14:02 MM, 
which were indeed reported by clinical studies (15, 16, 29). We are 
aware that HLA-C mRNA steady-state amounts were determined 
in PBMC and therefore may not allow disclosing variability in 
HLA-C expression in different tissues and cell types (3), which 
could be relevant to GVHD. Finally, this study focused on T cell 
alloreactivity and did not address NK cell-mediated responses 
that are HLA-C alloantigen-dependent through interaction with 
killer-immunoglobulin-like receptors and have been shown to be 
particularly relevant in haploidentical HSCT (37, 38).
Taken together and carefully controlling for potential con-
founding variables, our results suggest that HLA-C allorecognition 
in mismatched HSCT depends on the number of aa MM residues 
in the PBR, on HLA-DPB1 matching, on the TCR repertoire of 
the responding cells (although not measured directly in our 
experiments), and possibly on HLA-C expression. However, the 
complex interplay of these genetic factors is not straightforward. 
Clearly, neither HLA-C mRNA expression levels nor cell surface 
expression measured on heterozygous individuals could reli-
ably predict the strength of the alloresponse, as determined by 
an in vitro assay. Therefore, when selecting a partially matched 
unrelated donor for HSCT, we recommend that HLA-C MMs 
with ≥10 aa MM in the PBR and with a concomitant HLA-DPB1 
MM should be avoided. However, in specific cases, HLA-DPB1 
mismatching could be beneficial for the graft-versus-leukemia 
effect (39, 40). The identification of C*06:02 as a potentially per-
missive MM supports the importance of HLA-DPB1 matching 
because five of the six negative pairs were HLA-DPB1 matched, 
although they were characterized by >10 aa MMs in the PBR 
and by high levels of expression. Most likely, these results might 
be extrapolated to HLA-A or -B MMs, but this remains to be 
investigated in retrospective clinical studies or by in vitro assays. 
Thus for unrelated HSC donor searches that allow to procure only 
donors with single HLA class I disparities, this study confirms 
that it should be beneficial to prioritize HLA-DPB1-compatible 
donors. It also emphasizes that a pretransplant in vitro MLR assay 
with patient and donor lymphocytes, such as the one developed 
in this study, is a reliable way to predict CTL alloreactivity.
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